ABSTRACT
The purpose of this study was to determine the in vivo desensitization efficacy of a hypoallergenic variant of egg white ovomucoid third domain (DIII) in Balb/c mice model. We mapped the immunodominant B-cell epitopes of ovomucoid in Balb/c mice. A hypoallergenic ovomucoid third domain (GMFA) mutant isoform having ablated allergenicity against egg allergic patient's sera was used to desensitize DIII-sensitized Balb/c mice by intraperitoneal injections. Ovomucoid DIII generated high levels of plasma histamine and specific immunoglobulin (Ig)E levels, and increased Th2 type cytokine (IL-4). On the other hand, the allergic response of mice desensitized with the GMFA was found to be significantly inhibited and abrogated by prevention of anaphylaxis reactions, low histamine levels and increased Th1-type cytokine (INF-gamma). It was found that significantly higher levels of IL-10 and IL-12 were secreted in the desensitized group. Desensitization with the GMFA antigen also suppressed synthesis of DIII specific-IgE levels and enhanced specific IgG2a and IgG levels compared with the group treated with the DIII antigen. The present results indicated that hyposensitization with the GMFA can desensitize or down-regulate the allergic response in Balb/c mice and this hypoallergenic variant of ovomucoid DIII can shift an ongoing allergen-specific Th2 response towards a Th1 skewed response.
Subject(s)
Allergens/therapeutic use , Desensitization, Immunologic , Egg Hypersensitivity/therapy , Ovomucin/therapeutic use , Allergens/genetics , Animals , Cytokines/immunology , Female , Histamine/blood , Immunoglobulin E/blood , Immunoglobulin G/blood , Mice , Mice, Inbred BALB C , Ovomucin/genetics , Recombinant Proteins/therapeutic use , Spleen/cytology , Spleen/immunologyABSTRACT
Analysis was carried out of the results of complex therapy in 32 patients with acute destructive pancreatitis for which haemosorbtion on Ovosorb, a biospecific antiproteinase haemosorbent containing an immobilized ovomucoid, was used. The clinical efficiency of haemosorbtion was displayed as a decrease in gravity of endogenous intoxication and related functional and metabolic disturbances, as well as in a reduction of lethality from 24.7% to 6.2%.
Subject(s)
Hemoperfusion , Ovomucin/therapeutic use , Pancreatitis/therapy , Protease Inhibitors/therapeutic use , Acute Disease , Humans , Multiple Organ Failure/therapy , Pancreatitis/blood , Protease Inhibitors/metabolismABSTRACT
The biospecific antiproteinase haemosorbent (BAH) 'Ovosorb' containing, in the bulk of polyacryamide gel, the ovomucoid from whites of duck eggs, was used for a complex treatment of the experimental generalized purulent peritonitis and acute destructive pancreatitis in dogs. The efficiency of BAH was manifested in the significant reduction of lethality of the experimental animals, a more rapid liquidation of proteinasaemia, normalization in plasma of alpha 1-proteinase inhibitor and protein metabolism. Thus, by eliminating proteinases from circulation, Ovosorb contributes to the cessation of imbalance in the proteinase-inhibitor system and is efficient in the therapy of pathological states related to this imbalance.
Subject(s)
Ovomucin/therapeutic use , Pancreatitis/drug therapy , Peritonitis/drug therapy , Protease Inhibitors/therapeutic use , Acute Disease , Animals , Dogs , Pancreatitis/metabolism , Peritonitis/metabolism , SuppurationABSTRACT
Results of treatment of 32 patients with acute destructive pancreatitis are presented. Hemosorption on biospecific antiproteinase hemosorbent "OVOSORB" possessing the property of extraction of the excess of serine proteinases from blood plasma was used. High efficiency of the sorbent for treatment of destructive pancreatitis was shown. This effect was obtained at the expense of correction of hyperproteasemia, normalization of protein metabolism as well as prevention of the production and accumulation of middle molecule peptides possessing various pathological properties in the fluid media of the organism.
Subject(s)
Hemoperfusion/methods , Ovomucin/therapeutic use , Pancreatitis/therapy , Serine Proteinase Inhibitors/therapeutic use , Acute Disease , Combined Modality Therapy , Evaluation Studies as Topic , Humans , Pancreatitis/blood , Postoperative Care/methodsABSTRACT
The authors examined the efficacy of the biospecific antiprotease hemosorption Ovosorb containing ovomucoid from duck egg protein as part of polyacrylamide gel, which was used in the multimodality treatment for experimental diffuse pyoperitoneum and acute destructive pancreatitis in dogs. Ovosorb effectively diminished proteasemia, restored the plasma inhibitory potential by eliminating dysproteinemia, suppressed the production of secondary peptide endotoxins. These effects of the hemosorbent promoted the regression of endotoxicosis and the significant reduction in experimental animal deaths.
Subject(s)
Ovomucin/therapeutic use , Pancreatitis/therapy , Peritonitis/therapy , Protease Inhibitors/therapeutic use , Acute Disease , Animals , Combined Modality Therapy , Dogs , Female , MaleABSTRACT
The authors studied the character of the therapeutic action of some links of protein metabolism in connection with the use of hemosorption with a biospecific antiprotease hemosorbent "ovosorb" in the complex treatment of 24 patients with diffuse purulent peritonitis of appendicular genesis. It was found that the antiprotease biospecific hemosorbent is marked by high efficacy in the correction of protein metabolism and the consequent systemic disorders in patients with peritonitis of an appendicular genesis. It is shown that "ovosorb" removes selectively from hemocirculation active forms of proteinase of their complexes with inhibitors and, in contrast to carbon sorbents does not possess unspecific sorption of the inhibitors of proteinases and other blood plasms proteins.
Subject(s)
Appendectomy , Appendicitis/surgery , Drainage , Hemoperfusion/methods , Intestinal Perforation/therapy , Ovomucin/therapeutic use , Peritonitis/therapy , Acute Disease , Appendicitis/complications , Blood Proteins/drug effects , Combined Modality Therapy , Humans , Intestinal Perforation/etiology , Ovomucin/pharmacology , Peritonitis/blood , Peritonitis/etiology , Peritonitis/pathology , Postoperative Care , Rupture, Spontaneous , SuppurationABSTRACT
The pharmacodynamical properties of the duck ovomucoid and its effect on the development of experimental pancreatitis in rats have been studied. It has been shown that after intravenous injection the ovomucoid initially accumulated in the liver, kidneys and blood, while after intraperitoneal injection--mainly in the pancreas and kidneys. The inhibitor is removed from circulation by renal filtration, one-half of the injected protein being removed for 4 hr. For the treatment of experimental pancreatitis two modes of ovomucoid administration were used: intravenous and combined (intravenous/intraperitoneal). The ovomucoid intravenous injection in a dose of 16,300 ATU/kg/24 hr resulted in decrease of both the trypsin-like activity and the level of the trypsinogen activation peptide in the blood to the level in intact rats and also in reduction of the primary pancreas destruction. The same effect observed in the case of the ovomucoid combined injection, but with a lower intravenous dose.
Subject(s)
Ovomucin/pharmacokinetics , Ovomucin/therapeutic use , Pancreatitis/drug therapy , Trypsin/blood , Animals , Ducks , Iodine Radioisotopes , Mice , Mice, Inbred BALB C , Radioisotope Dilution Technique , Rats , Rats, Wistar , Tissue Distribution , Trypsin Inhibitors/bloodABSTRACT
The new antiprotease hemosorbent Ovosorb was tested during the performance of blood perfusion (BP) used as part of multimodality treatment of 11 patients. Of these, 2 presented with disseminated psoriasis, 3 with arthropathic psoriasis, 1 with psoriatic erythrodermia, 4 with atopic dermatitis, and 1 with recurrent urticaria. BP with the use of the hemosorbent Ovosorb produced the highest effect in patients with atopic dermatitis, psoriatic erythrodermia and recurrent urticaria; BP with Ovosorb was less effective in disseminated psoriasis. The clinical effect was lacking in patients with arthropathic psoriasis. Ovosorb possesses remarkable detoxifying properties, good blood compatibility; it does not provoke any complications in patients with different forms of psoriasis, atopic dermatitis, and urticaria.
Subject(s)
Acrylic Resins/therapeutic use , Hemoperfusion/methods , Ovomucin/therapeutic use , Protease Inhibitors/therapeutic use , Skin Diseases/therapy , Adult , Chronic Disease , Combined Modality Therapy , Female , Humans , Male , Middle AgedABSTRACT
The authors analyze the role of the initial inpatient stage of long-term oxygen therapy (LOT) in combined treatment of chronic pulmonary failure in patients with chronic obstructive bronchitis, lung emphysema, and pneumosclerosis. The treatment lasted 30 days both in the main and in the control groups. In addition to basic therapy, the main group patients received 38% O2 for 15 h a day. To decrease the risk of PaCO2 elevation with a possible respiratory disorder, particularly in patients with initial hypercapnia, it is suggested that a special oxygen test with simultaneous control of acid-base balance and gas composition of the arterial blood may be carried out. In contrast to the control group, the main group patients demonstrated an improvement of gas composition of the arterial blood and of the parameters such as the alveolar-arterial gradient according to O2, the physiological pulmonary shunt. The combined use of oxygen therapy and resistance at expiration made it possible to ameliorate a number of external respiration function parameters, diffusion lung capacity, and enhanced the effect of oxygen therapy. It is shown that patients with PaO2 may be given LOT within the range of 60-69 mm Hg, provided the pulmonary physiological shunt exceeds 20%.
